PMID- 35153733
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220216
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 12
DP  - 2021
TI  - Deciphering the Roles of Metformin in Alzheimer's Disease: A Snapshot.
PG  - 728315
LID - 10.3389/fphar.2021.728315 [doi]
LID - 728315
AB  - Alzheimer's disease (AD) is a prevalent neurodegenerative disease predominantly 
      affecting millions of elderly people. To date, no effective therapy has been 
      identified to reverse the progression of AD. Metformin, as a first-line 
      medication for Type 2 Diabetes Mellitus (T2DM), exerts multiple beneficial 
      effects on various neurodegenerative disorders, including AD. Evidence from 
      clinical studies has demonstrated that metformin use contributes to a lower risk 
      of developing AD and better cognitive performance, which might be modified by 
      interactors such as diabetic status and APOE-epsilon4 status. Previous mechanistic 
      studies have gradually unveiled the effects of metformin on AD pathology and 
      pathophysiology, including neuronal loss, neural dysfunction, amyloid-beta (Abeta) 
      depositions, tau phosphorylation, chronic neuroinflammation, insulin resistance, 
      impaired glucose metabolism and mitochondrial dysfunction. Current evidence 
      remains ambiguous and even conflicting. Herein, we review the current state of 
      knowledge concerning the mechanisms of metformin in AD pathology while 
      summarizing current evidence from clinical studies.
CI  - Copyright (c) 2022 Liao, Xu, Li, Ruan, Li and Liu.
FAU - Liao, Wang
AU  - Liao W
AD  - Department of Neurology, The Second Affiliated Hospital of Guangzhou Medical 
      University, Guangzhou, China.
AD  - Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 
      Guangzhou, China.
FAU - Xu, Jiaxin
AU  - Xu J
AD  - Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 
      Guangzhou, China.
FAU - Li, Bo
AU  - Li B
AD  - Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 
      Guangzhou, China.
FAU - Ruan, Yuting
AU  - Ruan Y
AD  - Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 
      Guangzhou, China.
AD  - Department of Rehabilitation Medicine, The Second Affiliated Hospital of 
      Guangzhou Medical University, Guangzhou, China.
FAU - Li, Tian
AU  - Li T
AD  - School of Basic Medicine, Fourth Military Medical University, Xi'an, China.
FAU - Liu, Jun
AU  - Liu J
AD  - Department of Neurology, The Second Affiliated Hospital of Guangzhou Medical 
      University, Guangzhou, China.
AD  - Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 
      Guangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220127
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC8829062
OTO - NOTNLM
OT  - AMPK
OT  - Alzheimer's disease
OT  - insulin
OT  - metformin
OT  - neuroinflammation
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/02/15 06:00
MHDA- 2022/02/15 06:01
PMCR- 2022/01/27
CRDT- 2022/02/14 05:29
PHST- 2021/06/22 00:00 [received]
PHST- 2021/12/29 00:00 [accepted]
PHST- 2022/02/14 05:29 [entrez]
PHST- 2022/02/15 06:00 [pubmed]
PHST- 2022/02/15 06:01 [medline]
PHST- 2022/01/27 00:00 [pmc-release]
AID - 728315 [pii]
AID - 10.3389/fphar.2021.728315 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Jan 27;12:728315. doi: 10.3389/fphar.2021.728315. 
      eCollection 2021.